medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (6)


IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 876-881
Archivo PDF: 91.35 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

  2. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, et al. Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012.

  3. Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary- care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-2.

  4. Burguete-Garcia AI, Conde-Gonzalez CJ, Jimenez-Mendez R, Juarez-Diaz Y, Meda-Monzon E, Torres-Poveda K, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica Mex 2011; 53(Suppl. 1): S7-S12.

  5. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31(Suppl. 2): 1-3.

  6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.

  8. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-8.

  9. de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, et al. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One 2012; 7: e31016.

  10. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl. 1): i36-i46.

  11. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-76.

  12. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338- 1345, 1345, e1331-1337.

  13. Li W, Zeng Y, Wang J, Zhou B, Zhang J, Zhang H, et al. Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay. Antiviral Res 2012; 94: 54-6.

  14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.

  15. Rodriguez-Torres MJL, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P; Latino Study Group. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-67.

  16. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.

  17. Fischer J, Bohm S, Scholz M, Muller T, Witt H, George J, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-10.

  18. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  19. Sixtos Alonso RAM, Dehesa Violante M, Sandoval Salas R, Chávez Ayala A, García Juárez I, Domínguez López A, Vargas Vorackova F, Sánchez Ávila JF, Uribe M. Polymorphism (SNP) RS12979860 OF IL28B in Mexican patients with chronic hepatitis C and its Association with virogical response to peg-ifn alpha 2b and ribavirin. J Hepatol 2011; 54: 1342.

  20. Entrez NCfBI. Database of single nucleotide polymorphisms (SNPs).

  21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  22. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  23. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology 2012.

  24. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012.

  25. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct acting antiviral agents for HCV? Hepatology 2012.




2020     |     www.medigraphic.com